Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The Second Antithyroid Drug Treatment is Effective in Relapsed Graves’ Disease Patients: A Median 11-Year Follow-Up Study
source: Thyroid: Official Journal of the American Thyroid Association
authors: Kim YA, Cho SW, Choi HS, Moon S, Moon JH, Kim KW, Park DJ, Yi KH, Park YJ, Cho BYsummary/abstract:
Antithyroid drug (ATD) is a widely used treatment for Graves’ disease (GD). However, its long-term efficiency remains unclear. This study investigated the long-term disease prognosis and predictive factors for relapse in ATD-treated GD patients.
Newly diagnosed, ATD-treated GD patients with at least four years of follow-up were recruited (n = 187). Remission was defined as maintaining a euthyroid status for more than one year after ATD withdrawal.
During 11.1 years (range 4.0-23.7 years) of median follow-up, overall, 51.9% of the newly diagnosed ATD-treated GD patients achieved remission, 32.1% continued ATD treatment, and 13.4% underwent other ablation treatments. The 10-year remission rates were higher in the first (34.2%) and second (25.5%) ATD courses than in any of the other subsequent ATD courses, and decreased as ATD treatments were repeated. The 10-year relapse rate was the highest after the third ATD treatment (71.4%) compared with that after the first (60.5%) and second (58.3%) courses. Longer duration of ATD treatment (odds ratio [OR] = 1.4 [confidence interval (CI) 1.2-1.7], p < 0.001), higher number of relapses (OR = 4.7 [CI 2.3-9.8], p < 0.001), and moderate to severe Graves’ ophthalmopathy (OR = 4.1 [CI 1.1-15.2], p = 0.032) were associated with persistent disease status.
A second course of ATD can be considered for GD patients after the first relapse because the chance of remission and the relapse rate are similar to the one after the first ATD treatment course. For GD patients with more than two relapses, or with an ATD treatment duration of more than four to five years, low-dose maintenance of ATD or ablative treatment needs to be considered.
A Second Course of Antithyroid Drug Therapy for Recurrent Graves’ Disease: An Experience in Endocrine PracticeObjective: There are scarce reports reg...
Predicting Risk of Recurrent Thyrotoxicosis Following Thionamide Withdrawal in Graves’ DiseaseBackground/Aim: Thionamides are a safe ...
Most Patients With Graves’ Disease Treated With Antithyroid Drugs Eventually Require Additional TherapiesGraves’ disease is the most common cau...
GDATF Community Conversations: Long-Term Use of Anti-Thyroid Drugshttps://www.youtube.com/watch?v=Az5B8FU7...
Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves’ Disease RelapseBackground: Thionamides are associated ...
Effects of Selenium on Short-Term Control of Hyperthyroidism due to Graves’ Disease Treated With Methimazole: ...Objective: In spite of previous conflic...
A Validated Tool Can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ D...Over-activity of the thyroid gland, call...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.